173 related articles for article (PubMed ID: 16827515)
1. A furore too far: the widespread disquiet undermining NICE.
Carlisle D
Health Serv J; 2006 Jun; 116(6011):14-5. PubMed ID: 16827515
[No Abstract] [Full Text] [Related]
2. Report blames NICE for hastening decline of UK biotech.
Moran N
Nat Biotechnol; 2009 Mar; 27(3):215-7. PubMed ID: 19270658
[No Abstract] [Full Text] [Related]
3. Nice or not so nice.
McColgan K
J Perioper Pract; 2010 Nov; 20(11):386. PubMed ID: 21162353
[No Abstract] [Full Text] [Related]
4. [Economic health technology assessment: challenges and perspectives].
Zerda A
Biomedica; 2014; 34(2):161-3. PubMed ID: 24967920
[No Abstract] [Full Text] [Related]
5. Data briefing. NICE (National Institute for Clinical Excellence).
Appleby J
Health Serv J; 2000 Jun; 110(5708):32. PubMed ID: 11183800
[No Abstract] [Full Text] [Related]
6. NICE and the public health.
Rawlins MD
Br J Clin Pharmacol; 2004 Dec; 58(6):575-80. PubMed ID: 15563355
[No Abstract] [Full Text] [Related]
7. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.
Birch S; Gafni A
Health Econ; 2002 Apr; 11(3):185-91. PubMed ID: 11921316
[No Abstract] [Full Text] [Related]
8. NICE reports. NICE to see you...
Bosanquet N
Health Serv J; 2003 Jun; 113(5860):30-1. PubMed ID: 12852103
[TBL] [Abstract][Full Text] [Related]
9. The HSJ interview: Andrew Dillon. The NICE guy. Interview by Lyn Whitfield.
Dillon A
Health Serv J; 2003 Jun; 113(5858):20-1. PubMed ID: 12808869
[No Abstract] [Full Text] [Related]
10. Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article.
; Burgess EP
N Z Med J; 2006 Jul; 119(1237):U2065; author reply U2065. PubMed ID: 16862207
[No Abstract] [Full Text] [Related]
11. NICE says drug for metastatic breast cancer is unaffordable for NHS.
Kmietowicz Z
BMJ; 2014 Apr; 348():g2888. PubMed ID: 24759923
[No Abstract] [Full Text] [Related]
12. The decade of NICE.
Rawlins MD
Lancet; 2009 Jul; 374(9686):351-2. PubMed ID: 19394075
[No Abstract] [Full Text] [Related]
13. A national technology assessment institute.
Howell A
Healthplan; 2003; 44(5):40-5. PubMed ID: 14556611
[No Abstract] [Full Text] [Related]
14. NICE puts clinical governance on the agenda.
Shuttleworth A
Prof Nurse; 1999 Jun; 14(9):605. PubMed ID: 10427294
[No Abstract] [Full Text] [Related]
15. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
16. Patients' views of explicit rationing: what are the implications for health service decision-making?
Devlin N; Appleby J; Parkin D
J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
[TBL] [Abstract][Full Text] [Related]
17. On more work for NICE.
Stevens S
Health Serv J; 2005 Oct; 115(5978):17. PubMed ID: 16273884
[No Abstract] [Full Text] [Related]
18. Trastuzumab emtansine and cost-based decision making.
The Lancet
Lancet; 2017 Jan; 389(10064):2. PubMed ID: 28091366
[No Abstract] [Full Text] [Related]
19. Evidence-informed evidence-making.
Chalkidou K; Walley T; Culyer A; Littlejohns P; Hoy A
J Health Serv Res Policy; 2008 Jul; 13(3):167-73. PubMed ID: 18573766
[TBL] [Abstract][Full Text] [Related]
20. A "bureausceptic" view of cancer drug rationing.
Crown J
Lancet; 2001 Nov; 358(9294):1660. PubMed ID: 11728537
[No Abstract] [Full Text] [Related]
[Next] [New Search]
